In developing drugs, it is important to optimize for a specific set of characteristics. Many of these characteristics can be measured experimentally after purchasing or synthesizing compounds. The high cost and time required to synthesize novel compounds makes it very important to rapidly identify optimal structures.
Quantitative Medicine’s Computational Research Engine (CoRE™) is designed to optimize. It utilizes sophisticated machine learning techniques to direct synthesis efforts to efficiently identify optimal structures. In previous studies, CoRE™ has been shown to reduce the required synthesis by 40-90% depending on the specific task. What would that impact do for your synthesis project?
In this webinar, you will have an opportunity to participate and ask questions about the CoRE™ technology as we review some of these previous studies with speakers from Quantitative Medicine, Sanofi, and Lundbeck.
Additionally, One Million Solutions in Health is offering an opportunity to further evaluate the CoRE™ technology. Through an application process, biopharmaceutical companies will be offered a free trial to join the Technology Evaluation Consortium™ (TEC) and participate in this project. We will present on this opportunity to join the TEC, which brings together pharmaceutical companies and technology providers to evaluate and validate new technologies.
Don’t wait, register now for this informative and thought-provoking webinar!
Josh Kangas, Ph.D.
Chief Science Officer
Richard Brennan, Ph.D.
Jorrit Hornberg, Ph.D.
Head of In Vitro Studies
Dawn Van Dam
President and CEO
One Million Solutions in Health